Clinical Study Of Concurrent Chemoradiotherapy Combined With Shenqifuzheng Injection In The Treatment Of Locally Advanced Non-small Cell Lung Cancer

Objective:To evaluate the effect of shenqifuzheng injection conbined with concurrent chemotherapy and radiotherapy to multi-tumor maker and T-cell subgroup in the treatment of locally advanced non-small cell lung cancer. And to observe the toxicity deduction and efficacy improvement effect by using shenqifuzheng in concurrent chemoradiotherapy.Methods:Choose forty-eight typical LANSCLC patients and randomly divide them into two groups. One group with 26 members, namely combination group, was given shenqifuzheng injection combined with concurrent chemoradiotherapy in the disease treatment. While the other group with 22 members, namely comparison group, was given concurrent chemoradiotherapy only. Both of the groups will receive chemotherapy of EP regimen, 3-Dimensional conformal radiotherapy was given with conventional fraction in 2Gy per fraction and five fractions per week. The total tumor doses were 60-70Gy. The patients of combination group were given shenqifuzheng injection 250 ml/d for consecutive two weeks for two courses additionally.Short-term curative efficacy was evaluated one month after therapy. Toxicities and effects were evaluated according to the criteria of WHO/ROGT.Results:Immune function of the two groups before treatment was not statistically different. One day after the treatment, CD3+,CD4+,CD4+/CD8+,NK of both of the groups were decreased, but the decrease was not statistically significant for combination group compared with before. While CD3+,CD4+,CD4+/CD8+ were decreased evidently for comparison group compared with before. One month later, CD3+,CD4+,CD4+/CD8+,NK of the combination group were measured to be statistically increased compared with before.TM were tested before the treatment and no statistically difference was found among the two groups. TM were tested to be reduced especially for those curative effective patients after the one month treatment. And among those the decrease of CYFRA21-1,CEA,CA-125 was tested to be statistically significant.Response rate of combination group was better than that of comparison group too, but the difference had no statistical significance.Grade 3-4 myelosuppression in hematologic toxicity rate of the combination group was significantly lower than that of the comparison group. The gastrointestinal adverse reactions, as well as acute radioactive esophagitis, pneumonia incidence of the combination group were all lower than that of the comparison group with no statistically difference.Meanwhile we gave KPS mark and body mass determination to all the objections at the beginning and a month after the therapy, it indicated that the life quality has been improved, especially for the combination group and the difference here between two groups was statistically significant.Conclusion:1. Shenqifuzheng injection combined with concurrent chemoradiotherapy can evidently relieve side effects of concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer, enhance the immune function of the organism and improve life quality. 2. It indicates significant reducing change of CYFRA21-1,CEA and CA125 after therapy compared with the indexes at the therapy beginning, especially to the patients that reach CR and PR curative effect. So the above three tumor markers can be seemed as a reference indexes to evaluate short-term curative efficacy.